• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用非参数动力学和动力学模型对药代动力学和药效学进行同时建模。

Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

作者信息

Unadkat J D, Bartha F, Sheiner L B

出版信息

Clin Pharmacol Ther. 1986 Jul;40(1):86-93. doi: 10.1038/clpt.1986.143.

DOI:10.1038/clpt.1986.143
PMID:3720181
Abstract

Three models, linked in series, can be used to analyze combined pharmacokinetic (PK) and pharmacodynamic (PD) data arising from non--steady-state experiments. A PK model relates dose to plasma drug concentration (Cp); a link model relates Cp to drug concentration at the effect site (Ce); and a PD model relates Ce to drug effect (E). All three submodels can be stated parametrically. Recently the use of a nonparametric PD submodel has been proposed (CLIN PHARMACOL THER 1984;35:733-41). In this article we use an extended nonparametric approach that represents both the PK and PD models nonparametrically, but retains a parametric link model. Cp data from several PK models and E data from several PD models were simulated. After the addition of noise to both the Cp and E data, they were analyzed by both the parametric and extended nonparametric methods. The methods were compared by how well they estimated the PD model. To assess robustness, the effect of misspecification of the PK submodel on the goodness of estimation of both methods was also compared. In the absence of model misspecification, the parametric method usually estimates the PD model better than the nonparametric method. However, this difference in the performances diminishes and even reverses when the PK model is misspecified. Because one can rarely be certain that model misspecification is absent, the nonparametric approach may offer a distinct advantage for routine analysis of PK/PD data.

摘要

三个串联的模型可用于分析非稳态实验产生的联合药代动力学(PK)和药效学(PD)数据。一个PK模型将剂量与血浆药物浓度(Cp)相关联;一个连接模型将Cp与效应部位的药物浓度(Ce)相关联;一个PD模型将Ce与药物效应(E)相关联。所有这三个子模型都可以用参数形式表示。最近有人提出使用非参数PD子模型(《临床药理学与治疗学》1984年;35:733 - 41)。在本文中,我们使用一种扩展的非参数方法,该方法以非参数形式表示PK和PD模型,但保留参数化的连接模型。模拟了来自几个PK模型的Cp数据和来自几个PD模型的E数据。在给Cp和E数据都添加噪声后,用参数方法和扩展非参数方法对它们进行分析。通过对PD模型的估计效果来比较这两种方法。为了评估稳健性,还比较了PK子模型的错误设定对两种方法估计优度的影响。在不存在模型错误设定的情况下,参数方法通常比非参数方法能更好地估计PD模型。然而当PK模型被错误设定时,这种性能差异会减小甚至反转。因为人们很少能确定不存在模型错误设定,所以非参数方法可能为PK/PD数据的常规分析提供明显优势。

相似文献

1
Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.使用非参数动力学和动力学模型对药代动力学和药效学进行同时建模。
Clin Pharmacol Ther. 1986 Jul;40(1):86-93. doi: 10.1038/clpt.1986.143.
2
Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.使用非参数药效学模型对药代动力学和药效学进行同步建模。
Clin Pharmacol Ther. 1984 Jun;35(6):733-41. doi: 10.1038/clpt.1984.104.
3
Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm.
Comput Appl Biosci. 1987 Nov;3(4):345-9. doi: 10.1093/bioinformatics/3.4.345.
4
Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.非稳态研究中的药代动力学-药效学(PK-PD)建模及动静脉药物浓度差异
Br J Clin Pharmacol. 1994 Nov;38(5):389-400. doi: 10.1111/j.1365-2125.1994.tb04372.x.
5
Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.群体药代动力学/药效学数据的同步分析与序贯分析II:方法的稳健性
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):405-16. doi: 10.1023/b:jopa.0000012999.36063.4e.
6
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.药代动力学/药效学(PK/PD)建模的基本概念。
Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13.
7
Indirect pharmacodynamic response models do not require any parametric pharmacokinetic model to be fitted to effect-time data.间接药效学反应模型不需要将任何参数药代动力学模型拟合到效应-时间数据。
Methods Find Exp Clin Pharmacol. 1997 Dec;19(10):723-9.
8
Using spline-enhanced ordinary differential equations for PK/PD model development.使用样条增强型常微分方程进行药代动力学/药效学(PK/PD)模型开发。
J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):553-71. doi: 10.1007/s10928-008-9101-9. Epub 2008 Nov 7.
9
Volterra series in pharmacokinetics and pharmacodynamics.药代动力学和药效学中的沃尔泰拉级数
J Pharmacokinet Pharmacodyn. 2003 Oct;30(5):337-62. doi: 10.1023/b:jopa.0000008158.30235.59.
10
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.群体药代动力学/药效学数据的同步分析与序贯分析I:最佳情况表现
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404. doi: 10.1023/b:jopa.0000012998.04442.1f.

引用本文的文献

1
Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease.多巴胺缓冲能力成像:一种用于帕金森病分期的药效功能磁共振成像方法。
Front Neurol. 2020 May 6;11:370. doi: 10.3389/fneur.2020.00370. eCollection 2020.
2
A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.重度痉挛患者鞘内注射巴氯芬的药代动力学-药效学模型。
Br J Clin Pharmacol. 2016 Jan;81(1):101-12. doi: 10.1111/bcp.12781.
3
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.
理解药代动力学/药效动力学关系中的滞后环难题。
J Pharm Pharm Sci. 2014;17(1):34-91.
4
Pharmacokinetics of non-intravenous formulations of fentanyl.芬太尼非胃肠外制剂的药代动力学。
Clin Pharmacokinet. 2013 Jan;52(1):23-36. doi: 10.1007/s40262-012-0016-7.
5
Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects.与阿托品相比,健康受试者中甲硫酸新斯的明的相对生物利用度和药效学作用。
Eur J Clin Pharmacol. 2012 Nov;68(11):1473-81. doi: 10.1007/s00228-012-1286-6. Epub 2012 Apr 21.
6
Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans.二氢可待因对人体缩瞳作用的药代动力学-药效学建模
Eur J Clin Pharmacol. 2007 Nov;63(11):1045-54. doi: 10.1007/s00228-007-0363-8. Epub 2007 Sep 5.
7
Investigation of a cellular pharmacodynamic model exhibiting sharp response sensitivity and tolerance.
J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):87-101. doi: 10.1007/s10928-006-9042-0. Epub 2006 Dec 12.
8
A 'bottom-up' approach for endo-PK/PD analysis.一种用于内镜药代动力学/药效学分析的“自下而上”方法。
Biopharm Drug Dispos. 2006 Oct;27(7):313-27. doi: 10.1002/bdd.508.
9
Pharmacokinetic-pharmacodynamic modelling: history and perspectives.药代动力学-药效学建模:历史与展望
J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):227-79. doi: 10.1007/s10928-005-9002-0. Epub 2006 Jan 11.
10
Dose-dependency and time-course of electrophysiologic short-term effects of VIAGRA: a case study.伟哥电生理短期效应的剂量依赖性和时程:一项案例研究。
Doc Ophthalmol. 2005 Mar-May;110(2-3):247-54. doi: 10.1007/s10633-005-0653-3.